

ChinaAMC Global ETF Series

**ChinaAMC Hang Seng Hong Kong  
Biotech Index ETF**

Unaudited Semi-Annual Report

For the period from  
1 January 2024 to 30 June 2024



**华夏基金**  
**ChinaAMC**

UNAUDITED SEMI-ANNUAL REPORT

ChinaAMC Hang Seng Hong Kong Biotech Index  
ETF (Stock Code: 03069 (HKD Counter), 09069  
(USD Counter) and 83069 (RMB Counter))  
(a Sub-Fund of ChinaAMC Global ETF Series)

For the period from 1 January 2024 to 30 June 2024

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

CONTENTS

	Pages
MANAGEMENT AND ADMINISTRATION	1 – 2
REPORT OF THE MANAGER TO THE UNITHOLDERS	3
UNAUDITED FINANCIAL STATEMENTS	
Statement of financial position	4
Statement of profit or loss and other comprehensive income	5 – 6
Statement of changes in net assets attributable to unitholders	7
Statement of cash flows	8
INVESTMENT PORTFOLIO (UNAUDITED)	9 – 10
MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED)	11 – 12
PERFORMANCE RECORD (UNAUDITED)	13
DETAILS OF SECURITY LENDING ARRANGEMENTS (UNAUDITED)	14 – 17
HOLDING OF COLLATERAL (UNAUDITED)	18
DISTRIBUTION DISCLOSURE (UNAUDITED)	19

**IMPORTANT:**

Any opinion expressed herein reflects the Manager's view only and is subject to change. For more information about the Sub-Fund, please refer to the prospectus of the Sub-Fund which is available at our website: <https://www.chinaamc.com.hk/product/chinaamc-hang-seng-hong-kong-biotech-index-etf-3069-hk-9069-hk/>

Investors should not rely on the information contained in this report for their investment decisions.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

#### MANAGEMENT AND ADMINISTRATION

##### **Manager**

China Asset Management (Hong Kong) Limited  
37/F, Bank of China Tower  
1 Garden Road  
Central, Hong Kong

##### **Directors of the Manager**

Gan Tian  
Li Yimei  
Li Fung Ming  
Sun Liqiang  
Yang Kun

##### **Trustee & Registrar**

HSBC Institutional Trust Services (Asia) Limited  
1 Queen's Road  
Central, Hong Kong

##### **Auditor**

Ernst & Young  
*Certified Public Accountants*  
*Registered Public Interest Entity Auditor*  
27/F, One Taikoo Place  
979 King's Road  
Quarry Bay, Hong Kong

##### **Conversion Agent**

HK Conversion Agency Services Limited  
1/F One & Two Exchange Square  
8 Connaught Place  
Central, Hong Kong

##### **Listing Agent**

Altus Capital Limited  
21 Wing Wo Street  
Central Hong Kong

##### **Legal Adviser to the Manager**

Simmons & Simmons  
30/F, One Taikoo Place  
979 King's Road  
Hong Kong

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

MANAGEMENT AND ADMINISTRATION (continued)

**Participating Dealers**

ABN AMRO Clearing Hong Kong Limited  
Suites 2407-2409, Level 24, Three Pacific Place,  
1 Queen's Road East  
Hong Kong

Guotai Junan Securities (Hong Kong) Limited  
26/F-28/F, Low Block  
Grand Millennium Plaza  
181 Queen's Road  
Central, Hong Kong

Barclays Bank PLC  
41/F Cheung Kong Center  
2 Queen's Road  
Central, Hong Kong

Haitong International Securities Company Limited  
22/F Li Po Chun Chambers  
189 Des Voeux Road  
Central, Hong Kong

BNP Paribas  
60/F., 61/F. and 63/F.,  
Two International Finance Centre  
8 Finance Street, Central, Hong Kong

Huatai Financial Holdings (Hong Kong) Limited  
62/F, The Center  
99 Queen's Road  
Central, Hong Kong

China International Capital Corporation Hong Kong  
Securities Limited  
29/F, One International Finance Centre  
1 Harbour View Street  
Central, Hong Kong

J.P. Morgan Broking (Hong Kong) Limited  
23/F-29/F, Chater House  
8 Connaught Road  
Central, Hong Kong

China Merchants Securities (HK) Co., Limited  
48/F, One Exchange Square  
8 Connaught Place  
Central, Hong Kong

Korea Investment & Securities Asia Limited  
Suite 3716-19, Jardine House  
1 Connaught Place  
Central, Hong Kong

Citigroup Global Markets Asia Limited  
50/F, Champion Tower  
Three Garden Road  
Central, Hong Kong

Merrill Lynch Far East Limited  
Level 55 Cheung Kong Center  
2 Queen's Road  
Central, Hong Kong

Credit Suisse Securities (Hong Kong) Limited  
87-92/F, 97-99/F,  
International Commerce Centre  
1 Austin Road West  
Kowloon, Hong Kong

Mirae Asset Securities (HK) Limited  
Units 8501, 8507-08, Level 85  
International Commerce Centre  
1 Austin Road West  
Kowloon, Hong Kong

DBS Vickers (Hong Kong) Limited  
16/F One Island East  
18 Westlands Road  
Quarry Bay, Hong Kong

The Hongkong and Shanghai Banking Corporation  
Limited  
Level 10 HSBC Main Building  
1 Queens's Road  
Central, Hong Kong

Goldman Sachs (Asia) Securities Limited  
68/F, Cheung Kong Center  
2 Queen's Road  
Central, Hong Kong

Yue Xiu Securities Company Limited  
Rooms Nos. 4917-4937, 49/F  
Sun Hung Kai Centre  
No.30 Harbour Road  
Wanchai, Hong Kong

Zhongtai International Securities Limited  
19/F, Li Po Chun Chambers  
189 Des Voeux Road  
Central, Hong Kong

## REPORT OF THE MANAGER TO THE UNITHOLDERS

### Introduction

The ChinaAMC Hang Seng Hong Kong Biotech Index ETF (the “Sub-Fund”) is a sub-fund of ChinaAMC Global ETF Series, an umbrella unit trust established under Hong Kong law by a trust deed dated 17 September 2015, as amended and restated from time to time, between China Asset Management (Hong Kong) Limited (the “Manager”) and HSBC Institutional Trust Services (Asia) Limited (the “Trustee”). The Sub Fund is a passively-managed ETF falling within Chapter 8.6 of the Code on Unit Trusts and Mutual Funds issued by the SFC. Units of the Sub-Fund (the “Units”) are traded on The Stock Exchange of Hong Kong Limited (the “SEHK”) like stocks. The Sub-Fund’s HKD counter (stock code: 03069) commenced trading on the SEHK on 18 March 2021. The Sub-Fund’s USD counter (stock code: 09069) and RMB counter (stock code: 83069) commenced trading on the SEHK on 30 June 2021 and 19 January 2024 respectively. The Sub-Fund is an index-tracking fund that seeks to track the performance of the Hang Seng Hong Kong-Listed Biotech Index (the “Index”).

The Manager will primarily use a full replication strategy through investing directly in Securities included in the Index with substantially the same weightings in which they are included in the Index.

The Manager may also use a representative sampling strategy where it is not possible to acquire certain Securities which are constituents of the Index due to restrictions or limited availability or where the Manager considers appropriate in its absolute discretion. This means that the Sub-Fund will invest directly in a representative sample of Securities that collectively has an investment profile that aims to reflect the profile of the Index. The Securities constituting the representative sample may or may not themselves be constituents of the Index, provided that the sample closely reflects the overall characteristics of the Index. In pursuing a representative sampling strategy, the Manager may cause the Sub-Fund to deviate from the index weighting on condition that the maximum deviation from the index weighting of any constituent will not exceed 4% or such other percentage as determined by the Manager after consultation with the SFC.

### Performance of the Sub-Fund

The investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Index. There can be no assurance that the Sub-Fund will achieve its investment objective.

The performance of the Sub-Fund is in below (Total Returns in respective currency<sup>1</sup>):

	1-Month	3-Month	Since Launch
The Index	-4.08%	-6.96%	-68.29% <sup>2</sup>
HKD Counter of the Sub-Fund (NAV-to-NAV)	-4.13%	-7.08%	-68.82% <sup>2</sup>
HKD Counter of the Sub-Fund (Market-to-Market)	-3.78%	-7.16%	-68.86% <sup>2</sup>
USD Counter of the Sub-Fund (NAV-to-NAV)	-3.98%	-6.86%	-73.26% <sup>3</sup>
USD Counter of the Sub-Fund (Market-to-Market)	-3.79%	-6.95%	-73.57% <sup>3</sup>

### Activities of the Sub-Fund

According to Bloomberg, the average daily trading volume of the Sub-Fund was 129,117 units from 01 January 2024 to 30 June 2024. As of 30 June 2024, there were 85,600,000 units outstanding.

China Asset Management (Hong Kong) Limited  
14 August 2024

<sup>1</sup> Source: Bloomberg, as of 30 June 2024. Performances of the benchmark Index and HKD Counter of the Sub-Fund are calculated in HKD while performances of USD Counter of the Sub-Fund are calculated in USD. Past performance figures shown are not indicative of the future performance of the Sub-Fund. With effect from 8 November 2021, the investment strategy of the Sub-Fund was changed. The performance of the Sub-Fund prior to 8 November 2021 was achieved under circumstances that no longer apply. With effect from 5 June 2023, the methodology of the Index of the Sub-Fund has been changed. RMB Counter commenced dealing on 19 January 2024 with track record of less than 6 months as at 30 June 2024. Performance information of RMB Counter is not presented.

<sup>2</sup> Calculated since 18 March 2021.

<sup>3</sup> Calculated since 30 June 2021.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF FINANCIAL POSITION (UNAUDITED)

As at 30 June 2024

	30 June 2024 (Unaudited) HKD	31 December 2023 (Audited) HKD
<b>ASSETS</b>		
Financial assets at fair value through profit or loss	638,066,251	622,783,523
Prepayments and other receivables	7,859	29,283
Dividend Receivables	4,117,329	-
Cash and cash equivalents	1,625,354	1,851,767
<b>TOTAL ASSETS</b>	<u><u>643,816,793</u></u>	<u><u>624,664,573</u></u>
<b>LIABILITIES</b>		
Management fee payable	257,642	252,219
Trustee and registrar fees payable	44,283	47,872
Other payables and accruals	238,793	482,462
<b>TOTAL LIABILITIES</b>	<u><u>540,718</u></u>	<u><u>782,553</u></u>
<b>EQUITY</b>		
Net asset value attributable to unitholders	<u><u>643,276,075</u></u>	<u><u>623,882,020</u></u>
<b>TOTAL LIABILITIES AND EQUITY</b>	<u><u>643,816,793</u></u>	<u><u>624,664,573</u></u>
Number of units in issue	<u><u>85,600,000</u></u>	<u><u>60,400,000</u></u>
Net asset value per unit	<u><u>7.5149</u></u>	<u><u>10.3292</u></u>

Note: The semi-annual report of the sub-funds have been prepared in accordance with the same accounting policies adopted in the 2023 annual financial statements.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

For the period from 1 January 2024 to 30 June 2024

	Period from 1 January 2024 to 30 June 2024 (Unaudited) HKD	Period from 1 January 2023 to 30 June 2023 (Unaudited) HKD
<b>INCOME</b>		
Dividend income	6,111,743	4,137,489
Interest income	5,314	5,105
Securities lending income	567,387	-
Other income	127,510	123,815
	<u>6,811,954</u>	<u>4,266,409</u>
<b>EXPENSES</b>		
Management fee <sup>2</sup>	( 1,392,494)	( 1,689,704)
Trustee and registrar fees <sup>1</sup>	( 243,191)	( 291,988)
Accounting fees <sup>1</sup>	( 34,908)	( 38,218)
Auditor's remuneration	( 65,424)	( 58,217)
Transaction fees <sup>1</sup>	( 306,293)	( 704,309)
Legal and professional fees	( 188,539)	( 17,955)
Safe custody and bank charges <sup>1</sup>	( 55,125)	( 67,379)
Other operating expenses	( 232,795)	( 250,598)
	<u>( 2,518,769)</u>	<u>( 3,118,368)</u>
<b>PROFIT BEFORE INVESTMENT LOSSES AND EXCHANGE DIFFERENCES</b>	<b>4,293,185</b>	<b>1,148,041</b>
<b>INVESTMENT LOSSES AND EXCHANGE DIFFERENCES</b>		
Net realised losses on financial assets at fair value through profit or loss	( 99,277,567)	( 221,105,587)
Net change in unrealised (losses)/gains on financial assets at fair value through profit or loss	( 110,152,005)	53,526,498
Foreign exchange differences	( 358)	( 490)
	<u>( 209,429,930)</u>	<u>( 167,579,579)</u>
<b>LOSS BEFORE TAX</b>	<b>( 205,136,745)</b>	<b>( 166,431,538)</b>
Withholding tax expense	( 172,340)	( 110,143)
<b>TOTAL LOSSES AND OTHER COMPREHENSIVE INCOME</b>	<b>( 205,309,085)</b>	<b>( 166,541,681)</b>



STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)  
(Continued)

For the period from 1 January 2024 to 30 June 2024

<sup>1</sup> During the period ended 30 June 2024, trustee and registrar fees, accounting fees and safe custody and bank charges incurred were paid to the Trustee or its connected person. Other respective amounts paid to the Trustee or its connected person were as follows:

	Period from 1 January 2024 to 30 June 2024 (Unaudited) HKD	Period from 1 January 2023 to 30 June 2023 (Unaudited) HKD
Transaction fees	32,786	49,193

<sup>2</sup> During the period ended 30 June 2024, other than management fees that paid to the Manager, no other amounts paid to the Manager or its connected persons.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS  
(UNAUDITED)

For the period from 1 January 2024 to 30 June 2024

	Period from 1 January 2024 to 30 June 2024 (Unaudited) HKD	Period from 1 January 2023 to 30 June 2023 (Unaudited) HKD
Balance at the beginning of the period	623,882,020	734,807,427
Issue of units during the period	274,668,400	66,829,960
Redemption of units during the period	( 49,965,260)	( 51,553,440)
Total comprehensive income	( 205,309,085)	( 166,541,681)
Balance at the end of the period	<u>643,276,075</u>	<u>583,542,266</u>
	Units	Units
Number of units in issue at the beginning of the period	60,400,000	54,200,000
Number of units issued during the period	31,400,000	5,400,000
Number of units redeemed during the period	( 6,200,000)	( 3,600,000)
Number of units in issue at the end of the period	<u>85,600,000</u>	<u>56,000,000</u>

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

STATEMENT OF CASH FLOWS (UNAUDITED)

For the period from 1 January 2024 to 30 June 2024

	Period from 1 January 2024 to 30 June 2024 (Unaudited) HKD	Period from 1 January 2023 to 30 June 2023 (Unaudited) HKD
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Loss before tax	( 205,136,745)	( 166,431,538)
Adjustments for:		
Dividend income	( 6,111,743)	( 4,137,489)
Interest income	( 5,314)	( 5,105)
	<u>( 211,253,802)</u>	<u>( 170,574,132)</u>
Decrease in financial assets at fair value through profit or loss	256,061,992	147,585,998
Increase in amount due from Manager	-	( 1,670)
Decrease in prepayment and other receivables	21,413	4,119
Increase in amount due to broker	-	1,553,655
Increase/(decrease) in management fee payable	5,423	( 58,052)
(Decrease)/increase in trustee and registrar fees payable	( 3,589)	2,962
(Decrease)/increase in other payables and accruals	( 243,669)	10,284
	<u>44,587,768</u>	<u>( 21,476,836)</u>
Cash generated/(used in) from operations		
Dividend received	1,994,414	2,070,635
Interest received	5,325	5,088
Tax paid	( 172,340)	( 110,143)
	<u>46,415,167</u>	<u>( 19,511,256)</u>
Net cash flows generated from/(used in) operating activities		
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of units*	3,323,680	43,075,220
Payments on redemption of units*	( 49,965,260)	( 22,912,640)
	<u>( 46,641,580)</u>	<u>20,162,580</u>
Net cash (used in)/generated from financing activities		
<b>NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>( 226,413)</b>	<b>651,324</b>
Cash and cash equivalents at the beginning of the period	1,851,767	1,171,912
<b>CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD</b>	<b><u>1,625,354</u></b>	<b><u>1,823,236</u></b>
<b>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</b>		
Cash at bank	1,625,354	1,823,236

\*During the period ended 30 June 2024, there were non-cash transactions of HKD271,344,720 (2023: HKD 23,754,740) on proceeds from issue of units and there were no non-cash transactions (2023: HKD 28,640,800) on payments on redemption of units.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

INVESTMENT PORTFOLIO (UNAUDITED)

As at 30 June 2024

	<b>Holdings</b>	<b>Fair value HKD</b>	<b>% of Net Assets</b>
<b>Listed equities</b>			
<b><u>Hong Kong</u></b>			
<b>Communications</b>			
YSB Inc	245,230	1,974,102	0.31
<b>Consumer, Cyclical</b>			
Alibaba Health Information Technology Ltd	3,789,518	11,861,191	1.84
JD Health International Inc	657,293	13,967,476	2.17
<b>Consumer, Non-cyclical</b>			
3D Medicines Inc	197,424	1,052,270	0.16
3Sbio Inc	2,297,800	14,797,832	2.30
Aim Vaccine Co Ltd	347,844	2,441,865	0.38
AK Medical Holdings Ltd	660,926	2,848,591	0.44
Akeso Inc	743,087	28,051,534	4.36
Alphamab Oncology	567,703	1,362,487	0.21
Ascentage Pharma Group International	273,400	6,985,370	1.09
Beigene Ltd	769,955	66,370,121	10.32
Carsgen Therapeutics Holdings Ltd	440,666	2,115,197	0.33
China Medical System Holdings Ltd	1,588,703	10,517,214	1.64
CSPC Pharmaceutical Group Ltd	9,989,836	62,136,780	9.66
Everest Medicines Ltd	210,000	4,111,800	0.64
Genscript Biotech Corp	1,625,359	13,522,987	2.10
Giant Biogene Holding Co Ltd	527,250	24,174,413	3.76
Hangzhou Tigermed Consulting Co Ltd	144,993	4,001,807	0.62
Hansoh Pharmaceutical Group Co Ltd	1,397,129	22,801,145	3.55
Hutchmed China Ltd	666,806	18,337,165	2.85
Innocare Pharma Ltd	1,411,060	6,801,309	1.06
Innovent Biologics Inc	1,624,344	59,775,859	9.29
Jinxin Fertility Group Ltd	2,598,244	7,223,118	1.12
Keymed Biosciences Inc	214,140	7,227,225	1.12
Lepu Biopharma Co Ltd	755,899	2,675,882	0.42
Lepu Sciencetech Medical Technology Shanghai Co Ltd	81,204	1,557,493	0.24
Livzon Pharmaceutical Group Inc	182,429	4,688,425	0.73
Luye Pharma Group Ltd	3,101,205	8,373,254	1.30
Microport Neurotech Ltd	274,643	1,713,772	0.27
Microport Scientific Corp	1,188,252	6,262,088	0.97
New Horizon Health Ltd	470,436	6,651,965	1.03
Pharmaron Beijing Co Ltd	337,367	2,850,751	0.44
Remegen Co Ltd	200,798	4,919,551	0.77
Shandong Boan Biotechnology Co Ltd	120,038	1,080,342	0.17
Shandong Weigao Group Medical Polymer Co Ltd	2,929,211	10,896,665	1.69

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

INVESTMENT PORTFOLIO (UNAUDITED) (Continued)

As at 30 June 2024

	Holdings	Fair value HKD	% of Net Assets
<b>Listed equities</b> (continued)			
<b>Hong Kong</b> (continued)			
<b>Consumer, Non-cyclical</b> (continued)			
Shanghai Fosun Pharmaceutical Group Co Ltd	584,794	7,730,977	1.20
Shanghai Microport Medbot Group Co Ltd	336,117	2,961,190	0.46
Shanghai Pharmaceutical Holding Co Ltd	432,993	5,083,338	0.79
Sichuan Kelun Biotech Biopharmaceutical Co Ltd	29,800	4,940,840	0.77
Sihuan Pharmaceutical Holdings Group Ltd	4,944,294	2,571,033	0.40
Simcere Pharmaceutical Group Ltd	1,075,744	6,164,013	0.96
Sino Biopharmaceutical Ltd	13,285,549	35,472,416	5.51
Sinopharm Group Co Ltd	790,065	16,393,849	2.55
SSY Group Ltd	1,573,542	6,640,347	1.03
United Laboratories Ltd	1,176,852	9,697,260	1.51
Wuxi Apptec Co Ltd	410,303	11,980,848	1.86
Wuxi Biologics Cayman Inc	4,513,364	52,084,221	8.10
WuXi XDC Cayman Inc	98,729	1,708,012	0.27
Zai Lab Ltd	1,168,410	15,656,694	2.43
<b>Utilities</b>			
China Resources Pharmaceutical Group Ltd	2,219,718	12,852,167	2.00
Total investments, at fair value		<u>638,066,251</u>	<u>99.19</u>
Total investments, at cost		<u><u>1,137,324,766</u></u>	

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED)

For the period from 1 January 2024 to 30 June 2024

	Holdings as at 1 January 2024	Additions	Disposals	Corporate Actions	Holdings as at 30 June 2024
<b>Listed equities</b>					
<b>Hong Kong</b>					
3D Medicines Inc	140,297	78,777	21,650	-	197,424
3Sbio Inc	1,764,942	889,872	357,014	-	2,297,800
Aim Vaccine Co Ltd	13,259	369,268	34,683	-	347,844
AK Medical Holdings Ltd	506,625	255,746	101,445	-	660,926
Akeso Inc	532,979	292,208	82,100	-	743,087
Alibaba Health Information Technology Ltd	2,449,080	1,924,165	583,727	-	3,789,518
Alphamab Oncology	436,354	219,880	88,531	-	567,703
Ascentage Pharma Group International	-	273,400	-	-	273,400
Beigene Ltd	621,403	292,966	144,414	-	769,955
Cansino Biologics Inc	83,924	3,614	87,538	-	-
Carsgen Therapeutics Holdings Ltd	338,548	170,602	68,484	-	440,666
China Medical System Holdings Ltd	1,219,951	615,651	246,899	-	1,588,703
China Resources Pharmaceutical Group Ltd	1,705,012	859,868	345,162	-	2,219,718
CSPC Pharmaceutical Group Ltd	8,077,269	4,067,632	2,155,065	-	9,989,836
Dingdang Health Technology Group Ltd	272,935	134,429	407,364	-	-
Everest Medicines Ltd	-	210,000	-	-	210,000
Genscript Biotech Corp	1,246,555	628,430	249,626	-	1,625,359
Giant Biogene Holding Co Ltd	360,037	225,090	57,877	-	527,250
Grand Pharmaceutical Group Ltd	1,444,960	62,106	1,507,066	-	-
Hangzhou Tigermed Consulting Co Ltd	111,352	56,198	22,557	-	144,993
Hansoh Pharmaceutical Group Co Ltd	1,073,355	540,394	216,620	-	1,397,129
Hutchmed China Ltd	512,097	258,127	103,418	-	666,806
Innocare Pharma Ltd	1,017,646	554,499	161,085	-	1,411,060
Innovent Biologics Inc	1,238,286	627,233	241,175	-	1,624,344
JD Health International Inc	503,486	254,538	100,731	-	657,293
Jinxin Fertility Group Ltd	1,969,269	993,377	364,402	-	2,598,244
Kangji Medical Holdings Ltd	330,354	162,520	492,874	-	-
Keymed Biosciences Inc	164,721	82,946	33,527	-	214,140
Lepu Biopharma Co Ltd	580,609	292,894	117,604	-	755,899
Lepu Scientech Medical Technology Shanghai Co Ltd	21,615	68,173	8,584	-	81,204

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED) (Continued)

For the period from 1 January 2024 to 30 June 2024

	Holdings as at 1 January 2024	Additions	Disposals	Corporate Actions	Holdings as at 30 June 2024
<b>Listed equities</b> (continued)					
<b>Hong Kong</b> (continued)					
Livzon Pharmaceutical Grp Inc	-	200,528	18,099	-	182,429
Luye Pharma Group Ltd	2,382,245	1,201,098	482,138	-	3,101,205
Microport Neurotech Ltd	210,382	106,815	42,554	-	274,643
Microport Scientific Corp	912,371	460,230	184,349	-	1,188,252
New Horizon Health Ltd	331,181	163,135	23,880	-	470,436
Pharmaron Beijing Co Ltd	259,188	130,739	52,560	-	337,367
Remegen Co Ltd	154,301	77,540	31,043	-	200,798
Sciclone Pharmaceuticals Holdings Ltd	-	477,000	477,000	-	-
Shandong Boan Biotechnology Co Ltd	13,861	118,326	12,149	-	120,038
Shandong Weigao Group Medical Polymer Co Ltd	2,250,360	1,134,533	455,682	-	2,929,211
Shanghai Fosun Pharmaceutical Group Co Ltd	449,389	226,199	90,794	-	584,794
Shanghai Microport Medbot Group Co Ltd	301,347	132,016	97,246	-	336,117
Shanghai Pharmaceutical Holding Co Ltd	332,541	167,763	67,311	-	432,993
Sichuan Kelun Biotech Biopharmaceutical Co Ltd	-	29,800	-	-	29,800
Sihuan Pharmaceutical Holdings Group Ltd	3,798,651	1,914,792	769,149	-	4,944,294
Simcere Pharmaceutical Group Ltd	841,611	420,419	186,286	-	1,075,744
Sino Biopharmaceutical Ltd	10,205,339	5,146,731	2,066,521	-	13,285,549
Sinopharm Group Co Ltd	606,794	306,022	122,751	-	790,065
Sipai Health Technology Co Ltd	189,910	93,403	283,313	-	-
SSY Group Ltd	1,208,344	608,988	243,790	-	1,573,542
United Laboratories Ltd	903,880	455,080	182,108	-	1,176,852
Wuxi Apptec Co Ltd	327,750	165,195	82,642	-	410,303
Wuxi Biologics Cayman Inc	1,500,605	3,286,774	274,015	-	4,513,364
WuXi XDC Cayman Inc	-	108,628	9,899	-	98,729
YSB Inc	5,780	263,775	24,325	-	245,230
Zai Lab Ltd	894,162	450,987	176,739	-	1,168,410
Total of equity securities	56,816,912	33,311,119	14,857,565	-	75,270,466

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

PERFORMANCE RECORD (UNAUDITED)

For the period from 1 January 2024 to 30 June 2024

**1. Net Asset Value**

	Net asset value per unit HKD	Total net asset value HKD
As at:		
30 June 2024 (Unaudited)	7.5149	643,276,075
31 December 2023 (Audited)	10.3292	623,882,020
31 December 2022 (Audited)	13.5573	734,807,427

**2. Highest issue and lowest redemption prices per unit**

	Highest issue unit price HKD	Lowest redemption unit price HKD
Period from 1 January 2024 to 30 June 2024 (Unaudited)	10.0648	7.2718
For the year ended 31 December 2023 (Audited)	15.6496	9.6189
For the year ended 31 December 2022 (Audited)	16.8542	9.6822
Period from 18 March 2021 (date of inception) to 31 December 2021 <sup>2</sup> (Audited)	29.2558	15.9905

**3. Comparison of the scheme performance and the actual index performance <sup>1</sup>**

The table below illustrates the comparison between the Sub-Fund's performance (Market-to-Market) and that of the index during the following periods:

	The index	HKD counter of the Sub-Fund	USD counter of the Sub-Fund
Period from 1 January 2024 to 30 June 2024 (Unaudited)	-27.13%	-27.18%	-26.97%
For the year ended 31 December 2023 (Audited)	-23.15%	-22.81%	-23.12%
For the year ended 31 December 2022 (Audited)	-17.72%	-18.77%	-18.36%
Period from 18 March 2021 (date of inception) to December 2021 <sup>2</sup> (Audited)	-31.18%	-31.80%	-42.34%

<sup>1</sup> Past performance figures shown are not indicative of the future performance of the Sub-Fund.

<sup>2</sup> The performance of the USD counter of the Sub-Fund covers the period from 18 March 2021 to 31 December 2021.



DETAILS OF SECURITY LENDING ARRANGEMENTS (UNAUDITED)

**Breakdown of securities lending transactions**

Securities Lending transactions

Securities Lending transactions as at 30 June 2024 are summarized as below.

Counter Party	Securities on loan	Collateral type	Remaining contractual maturity	Currency	Geographical location of counterparty	Settlement/ clearing	Fair value of securities lent*	% of Net Asset Value
The Hong Kong & Shanghai Banking Corporation Ltd	3D Medicines Inc	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	373,241	0.06%
The Hong Kong & Shanghai Banking Corporation Ltd	3Sbio Inc	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	4,929,971	0.77%
The Hong Kong & Shanghai Banking Corporation Ltd	Aim Vaccine Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,500,616	0.23%
The Hong Kong & Shanghai Banking Corporation Ltd	AK Medical Holdings Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	2,580,386	0.40%
The Hong Kong & Shanghai Banking Corporation Ltd	Akeso Inc	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	16,851,258	2.62%
The Hong Kong & Shanghai Banking Corporation Ltd	Alphamab Oncology	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,221,210	0.19%
The Hong Kong & Shanghai Banking Corporation Ltd	Carsgen Therapeutics Holdings Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,320,468	0.21%
The Hong Kong & Shanghai Banking Corporation Ltd	Hangzhou Tigermed Consulting Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	3,679,827	0.57%
The Hong Kong & Shanghai Banking Corporation Ltd	Hutchmed China Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	16,542,914	2.57%
The Hong Kong & Shanghai Banking Corporation Ltd	Innocare Pharma Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	2,130,042	0.33%

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

DETAILS OF SECURITY LENDING ARRANGEMENTS (UNAUDITED) (Continued)

Securities Lending transactions (Continued)

Counter Party	Securities on loan	Collateral type	Remaining contractual maturity	Currency	Geographical location of counterparty	Settlement/ clearing	Fair value of securities lent*	% of Net Asset Value
The Hong Kong & Shanghai Banking Corporation Ltd	Jinxin Fertility Group Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	2,440,280	0.38%
The Hong Kong & Shanghai Banking Corporation Ltd	Keymed Biosciences Inc	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	6,553,017	1.02%
The Hong Kong & Shanghai Banking Corporation Ltd	Lepu Biopharma Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	2,478,021	0.39%
The Hong Kong & Shanghai Banking Corporation Ltd	Lepu Sciencetech Medical Technology Shanghai Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,237,204	0.19%
The Hong Kong & Shanghai Banking Corporation Ltd	Livzon Pharmaceutical Grp Inc	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,612,162	0.25%
The Hong Kong & Shanghai Banking Corporation Ltd	Luye Pharma Group Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	2,918,150	0.45%
The Hong Kong & Shanghai Banking Corporation Ltd	Microport Neurotech Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,105,493	0.17%
The Hong Kong & Shanghai Banking Corporation Ltd	Microport Scientific Corp	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	5,872,864	0.91%
The Hong Kong & Shanghai Banking Corporation Ltd	Pharmaron Beijing Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,793,732	0.28%
The Hong Kong & Shanghai Banking Corporation Ltd	Remegen Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,793,572	0.28%
The Hong Kong & Shanghai Banking Corporation Ltd	Shandong Boan Biotechnology Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	899,493	0.14%

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

DETAILS OF SECURITY LENDING ARRANGEMENTS (UNAUDITED) (Continued)

Securities Lending transactions (Continued)

Counter Party	Securities on loan	Collateral type	Remaining contractual maturity	Currency	Geographical location of counterparty	Settlement/clearing	Fair value of securities lent*	% of Net Asset Value
The Hong Kong & Shanghai Banking Corporation Ltd	Shanghai Fosun Pharmaceutical Group Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	6,892,512	1.07%
The Hong Kong & Shanghai Banking Corporation Ltd	Shanghai Microport Medbot Group Co Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	2,762,294	0.43%
The Hong Kong & Shanghai Banking Corporation Ltd	Sihuan Pharmaceutical Holdings Group Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	917,363	0.14%
The Hong Kong & Shanghai Banking Corporation Ltd	Simcere Pharmaceutical Group Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	2,161,676	0.34%
The Hong Kong & Shanghai Banking Corporation Ltd	WuXi XDC Cayman Inc	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	1,121,736	0.17%
The Hong Kong & Shanghai Banking Corporation Ltd	YSB Inc	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	674,528	0.11%
The Hong Kong & Shanghai Banking Corporation Ltd	Zai Lab Ltd	Government bond	Open tenor	HKD	Hong Kong	Triparty Collateral	14,069,306	2.19%
							<u>108,433,336</u>	<u>16.86%</u>

<sup>1</sup> Securities lent information was based on the Sub-Fund's accounting record. Foreign currency transactions are translated into the functional currency using the exchange rate prevailing at the date of translations, and the assets and liabilities are translated into the functional currency using the exchange rate prevailing at the period end date.

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

DETAILS OF SECURITY LENDING ARRANGEMENTS (UNAUDITED) (Continued)

Global data

	As at 30 June 2024 <i>HKD</i>
Amount of securities on loan as a proportion of total lendable assets <sup>2</sup>	5.06%
Amount of securities on loan as a proportion of total net asset value <sup>2</sup>	16.86%

<sup>2</sup> Securities lent information was based on the Sub-Fund's accounting record. Foreign currency transactions are translated into the functional currency using the exchange rate prevailing at the date of translations, and the assets and liabilities are translated into the functional currency using the exchange rate prevailing at the period end date.

Concentration data

30 June 2024		
	Amount collateral received <i>HKD</i>	% of Net Asset Value
Top ten largest collateral issuers		
Japan	113,865,888	17.70%
Top ten counterparties of securities lending transactions	Fair value of securities on loan <i>HKD</i>	% of Net Asset Value
The Hong Kong & Shanghai Banking Corporation Ltd	108,433,336	16.86%

Revenue and expenses relating to securities financing transactions

Revenue retained by the Sub-Fund and expenses incurred relating to each type of securities financing transactions are shown below.

	Period ended 30 June 2024 <i>HKD</i>
Securities Lending Transactions	
Revenue retained by the Sub-Fund	497,767
Direct expenses paid to the Manager	-

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

HOLDING OF COLLATERAL (UNAUDITED)

Holdings of Collateral

Collateral provider**	Nature of the collateral	Maturity Tenor	Currency denomination	Value of the collateral* <i>HKD</i>	% of net asset value covered by collateral
The Hong Kong & Shanghai Banking Corporation Ltd	Government Bond	20 December 2037	JPY	113,865,888	17.70%
				<u>113,865,888</u>	<u>17.70%</u>

\* As at 30 Jun 2024, the credit ratings of fixed income collateral are at or above investment grade.

\*\* As at 30 Jun 2024, the credit ratings of counterparties are at or above investment grade.

Custody/safe-keeping arrangement

As at 30 June 2024

Name of custodians	Amount of collateral received <i>HKD</i>	% of collateral posted by the scheme
<b>Segregated accounts</b>		
JP Morgan Luxembourg SA	113,865,888	100.00%
	<u>113,865,888</u>	<u>100.00%</u>

ChinaAMC Hang Seng Hong Kong Biotech Index ETF  
(a Sub-Fund of ChinaAMC Global ETF Series)

DISTRIBUTION DISCLOSURE (UNAUDITED)

For the period from 1 January 2024 to 30 June 2024

The Manager intends to distribute income to Unitholders at least annually (usually in December), subject to the Manager's discretion, having regard to the Sub-Fund's net income after fees and costs. All Units (whether USD, HKD or RMB traded Units) will receive distributions in HKD only. Distributions may be paid out of capital or effectively out of capital as well as income at the Manager's discretion.

The Sub-Fund did not make any distribution during the period ended 30 June 2024.

